John Joseph
Grant Category: Fulbright-Nehru Postdoctoral Research Fellowships
Project Title: Infection-Responsive Hydrogel System for the Treatment of Spontaneous Bacterial Peritonitis
Field of Study: Bioengineering
Home Institution: Amrita Centre for Nanosciences and Molecular Medicine, Kochi, Kerala
Host Institution: Brigham and Women’s Hospital, Harvard Medical School, Boston, MA  
Grant Start Month: October, 2019
Duration of Grant: Twenty four months

John Joseph
Brief Bio:

Dr. John Joseph is a postdoctoral fellow at the Amrita Centre for Nanosciences and Molecular Medicine, Kerala. He was awarded a PhD degree in the field of nanomedical sciences. His main research focus was the development of nanotextiles from polymeric nanofibers for vascular graft applications. He currently holds patents in the U.S. and India. Dr. Joseph is a recipient of many prestigious awards such as a Commonwealth scholarship, CSIR senior research fellowship, and DBT postgraduate fellowship. As a part of the Commonwealth scholarship, Dr. Joseph had the opportunity to work as a visiting PhD fellow at University of Bristol, U.K., for a period of one year. During this period, he carried out large animal studies on the developed vascular graft at one of the world’s leading centers for translational cardiovascular research. Dr. Joseph has published several research articles in high-impact journals.

As a part of the Fulbright-Nehru postdoctoral fellowship, Dr. Joseph is carrying out research at Dr. Karp’s lab at Harvard Medical School. His research emphasis is on the development of a novel drug delivery platform to treat a deadly and recurring bacterial infection in patients with liver cirrhosis, which is the 12th leading cause of death in the world. The platform is based on an injectable system that provides on-demand delivery of antibiotics in the presence of an infection. This approach is expected to work as an alternate therapy to reduce the daily administration of oral antibiotics, which by itself is associated with several adverse effects. This pragmatic approach should reduce the mortality rate and improve the quality of life in cirrhosis patients.